The Online Investor
Autolus Therapeutics PLC (AUTL)

Autolus Therapeutics is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. Using Co.'s broad suite of proprietary and modular T cell programming technologies, Co. is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells.
Company Name: 
Autolus Therapeutics PLC
Number of ETFs Holding AUTL: 
Total Market Value Held by ETFs: 
Quotes delayed 20 minutes

Strong Buy (3.86 out of 4)
78th percentile
(ranked higher than approx. 78% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Autolus Therapeutics PLC (AUTL) Page | The Online Investor Page |

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.